Stemline Therapeutics (STML) Misses Q1 EPS by 1c

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $121.4 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Elauwit Connection, Inc. (ELWT) Misses Q2 EPS by 44c
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns